Drug Trial Radar · NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
880
Planned (sponsor's estimate)
Start
Apr 17, 2023
Primary completion
Jul 2030
Study completion Jul 2030
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Mar 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.
Conditions
- Breast Cancer
- Solid Tumors, Adult
Interventions
STX-478Drug
STX-478 is a mutant-selective PI3Kα inhibitor
FulvestrantDrug
Fulvestrant
RibociclibDrug
Ribociclib
PalbociclibDrug
Palbociclib
LetrozoleDrug
Letrozole
AnastrozoleDrug
Anastrozole
ExemestaneDrug
Exemestane
TamoxifenDrug
Tamoxifen
AbemaciclibDrug
Abemaciclib
ImlunestrantDrug
Imlunestrant
MetforminDrug
Metformin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)Time frame: First 28 days of treatment
- Proportion of participants who experience at least 1 DLT during the first 28 days of treatmentTime frame: First 28 days of treatment
- Objective response rate (ORR) defined as the percentage of participants with partial response or complete response based on RECIST 1.1Time frame: 12 months
- Incidence of TEAEs/SAEs ≥ grade 2Time frame: 12 months
- Frequency of TEAEs according to CTCAE v5.0 criteriaTime frame: 12 months
Locations
65 sites in 9 countries. Site status is shown where the registry gives one.
Ellison Clinic at Saint John's
Los Angeles, California · Recruiting
UCSF Medical Center at Mission Bay
San Francisco, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Yale-New Haven Hospital
New Haven, Connecticut · Completed
Florida Cancer Specialists ORLANDO/DDU
Lake Mary, Florida · Completed
Moffitt Cancer Center
Tampa, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Louisiana State University Health Sciences Center
New Orleans, Louisiana · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Terminated
START Midwest
Grand Rapids, Michigan · Recruiting
Saint Luke's Cancer Institute
Kansas City, Missouri · Recruiting
Washington University
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
UH Cleveland Medical Center
Cleveland, Ohio · Recruiting
Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio · Recruiting
Providence Cancer Institute Franz Clinic
Portland, Oregon · Recruiting
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Mary Crowley Cancer Research Center
Dallas, Texas · Completed
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
USO-Virginia Cancer Specialists, PC
Fairfax, Virginia · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, France · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Institut Paoli-Calmettes
Marseille, France · Recruiting
Centre Antoine-Lacassagne
Nice, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Not yet recruiting
Mater Misericordiae Hospital
Dublin, Ireland · Recruiting
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo
Alessandria, Italy · Recruiting
Spedali Civili di Brescia
Brescia, Italy · Not yet recruiting
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.